Sensorion secures approval for HearConnex Phase I/II study in France

​

Sensorion has received authorisation from the French ANSM for its clinical trial application to begin HearConnex, a Phase I/II study assessing its investigational gene therapy SENS-601 for hearing loss treatment related to GJB2 gene mutations.

The post Sensorion secures approval for HearConnex Phase I/II study in France appeared first on Hospital Management.

 

Back to the Featured Stories
Sensorion secures approval for HearConnex Phase I/II study in France

Featured Stories

Médunik and Biocodex sign exclusive agreement for Diacomit in Canada
HR HealthCare rolls out Liv catheter for female self-catheterisation
Norroy receives China’s clearance for Phase III study of 177Lu-NYM032
Novartis signs drug delivery deal with Alteogen
FDA grants 510(k) clearance to Medibyt’s CPETWise solution

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us